MX2021007852A - Inhibidor del receptor del factor de crecimiento epidermico (egfr) resistente al tratamiento mutante l718 y/o l792. - Google Patents

Inhibidor del receptor del factor de crecimiento epidermico (egfr) resistente al tratamiento mutante l718 y/o l792.

Info

Publication number
MX2021007852A
MX2021007852A MX2021007852A MX2021007852A MX2021007852A MX 2021007852 A MX2021007852 A MX 2021007852A MX 2021007852 A MX2021007852 A MX 2021007852A MX 2021007852 A MX2021007852 A MX 2021007852A MX 2021007852 A MX2021007852 A MX 2021007852A
Authority
MX
Mexico
Prior art keywords
egfr inhibitor
mutation
resistant egfr
mutant treatment
exon
Prior art date
Application number
MX2021007852A
Other languages
English (en)
Inventor
Takao Uno
Shinichi Hasako
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2021007852A publication Critical patent/MX2021007852A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona un agente antitumoral para tratar a un paciente con tumor maligno que expresa EGFR que tiene por lo menos una mutación seleccionada del grupo que consiste en la mutación L718X en el exón 18 y la mutación L792X en el exón 20, en donde X representa un residuo de aminoácidos arbitrario, el agente antitumoral comprende (S)-N-(4-amino-6-metil-5-(quinolin -3-il)-8,9-dihidropirimido[5,4-b]indolizin-8-il)acrilamida (Compuesto (A)) o una sal de la misma.
MX2021007852A 2018-12-28 2019-12-27 Inhibidor del receptor del factor de crecimiento epidermico (egfr) resistente al tratamiento mutante l718 y/o l792. MX2021007852A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018247131 2018-12-28
PCT/JP2019/051377 WO2020138400A1 (en) 2018-12-28 2019-12-27 L718 and/or l792 mutant treatment-resistant egfr inhibitor

Publications (1)

Publication Number Publication Date
MX2021007852A true MX2021007852A (es) 2021-08-11

Family

ID=69174561

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007852A MX2021007852A (es) 2018-12-28 2019-12-27 Inhibidor del receptor del factor de crecimiento epidermico (egfr) resistente al tratamiento mutante l718 y/o l792.

Country Status (13)

Country Link
US (1) US20220072000A1 (es)
EP (1) EP3902548A1 (es)
JP (1) JP7303303B2 (es)
KR (1) KR20210110329A (es)
CN (1) CN113423403A (es)
AU (1) AU2019417691A1 (es)
BR (1) BR112021012687A2 (es)
CA (1) CA3124750A1 (es)
IL (1) IL284330A (es)
MX (1) MX2021007852A (es)
SG (1) SG11202106986VA (es)
WO (1) WO2020138400A1 (es)
ZA (1) ZA202104679B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022007841A1 (zh) * 2020-07-09 2022-01-13 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2922077C (en) 2013-08-22 2018-06-26 Taiho Pharmaceutical Co., Ltd. Quinoline-substituted compound
EP3143015B1 (en) * 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
JOP20190073A1 (ar) * 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
PT3677266T (pt) * 2017-09-01 2024-03-04 Taiho Pharmaceutical Co Ltd Inibidor seletivo de egfr com mutação no exão 18 e/ou exão 21

Also Published As

Publication number Publication date
ZA202104679B (en) 2023-12-20
JP2022522573A (ja) 2022-04-20
EP3902548A1 (en) 2021-11-03
CA3124750A1 (en) 2020-07-02
BR112021012687A2 (pt) 2021-09-28
KR20210110329A (ko) 2021-09-07
SG11202106986VA (en) 2021-07-29
IL284330A (en) 2021-08-31
TW202038965A (zh) 2020-11-01
US20220072000A1 (en) 2022-03-10
JP7303303B2 (ja) 2023-07-04
AU2019417691A1 (en) 2021-07-22
WO2020138400A1 (en) 2020-07-02
CN113423403A (zh) 2021-09-21

Similar Documents

Publication Publication Date Title
JOP20200044A1 (ar) مثبط انتقائي egfr طافر exon 18 و/أو exon 21
MX2021013661A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos.
MX2021013662A (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
SG11201903875QA (en) Selective inhibitor of exon 20 insertion mutant egfr
SG11201907038WA (en) Quinazoline compound
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2020012261A (es) Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
JOP20200209A1 (ar) مثبطات cd73
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
TW200628156A (en) Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
PH12019502197A1 (en) Macrocyclic compound and uses thereof
MX2021015628A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
EP4085053A4 (en) CANCER TREATMENT WITH CDK12/13 INHIBITORS
ZA202104679B (en) L718 and/or l792 mutant treatment-resistant egfr inhibitor
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment
MXPA05011233A (es) Vectores peptidicos.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2021011699A (es) Derivados de quinolina y su uso para el tratamiento del cancer.
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
EP3987032A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
MX2022006278A (es) Proteinas de salmon uk 114 para uso en el tratamiento, diagnostico y prevencion de tumores malignos.